
ArcherDx
Founded Year
2013Stage
Acquired - II | AcquiredTotal Raised
$150MValuation
$0000About ArcherDx
ArcherDX offers a bioinformatics platform for targeted sequencing applications featuring proprietary Anchored Multiplexed PCR (AMP) chemistry in a lyophilized format.On June 22nd, 2020, ArcherDx was acquired by Invitae at a valuation between $325 and $1400M.
ArcherDx Headquarter Location
2477 55th Street Suite 202
Boulder, Colorado, 80301,
United States
877-771-1093
Expert Collections containing ArcherDx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ArcherDx is included in 6 Expert Collections, including Cancer.
Cancer
105 items
Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'
Medical Devices
8,520 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Omics
1,265 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Digital Health
12,801 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health Monitoring & Diagnostics
76 items
Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx
Health IT
7,900 items
ArcherDx Patents
ArcherDx has filed 18 patents.
The 3 most popular patent topics include:
- Molecular biology
- Biotechnology
- DNA
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
11/2/2017 | 3/16/2021 | Molecular biology, Clusters of differentiation, Immune system, Immunology, DNA | Grant |
Application Date | 11/2/2017 |
---|---|
Grant Date | 3/16/2021 |
Title | |
Related Topics | Molecular biology, Clusters of differentiation, Immune system, Immunology, DNA |
Status | Grant |
Latest ArcherDx News
Jan 17, 2022
News provided by Share this article Share this article This report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions. Is genomic cancer testing bouncing back? What has happened to Direct to Consumer testing? Will all newborns receive Whole Genomic Sequencing at birth? The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life, and new problems for the industry. Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. Genetic Testing Recent Developments Natera Launches Tumor Genomic Profiling Assay 23andMe To Go Public Ancestry Quits Health Offering Aetna Coverage for NIPT to Include All Pregnancies Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing Tumor, Germline Testing of Cancer Patients Can Give Discordant Results Invitae Completes Acquisition of ArcherDx Prenetics Receives $15M Investment Preconception Carrier Screening Trial Begins in Australia Genetic Testing Clinical Use Just Beginning Fulgent Genetics Q1 Revenues Jump 44 Percent Blueprint Genetics, NICER Consortium Developing Genetic Test for Immunologic, Hematologic Disorders Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests Invitae Acquires Three Companies: YouScript, Genelex, Diploid PerkinElmer SCID Test Chosen for Newborn Screening Evaluation in England Germline Cancer Risk Mutations Sometimes Reported in Tumor Testing Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients Phosphorus Offers DNA Testing to Assess Disease Risk Arivale Shuts Down Personalized Wellness Business ArcherDX Acquires Baby Genes
When was ArcherDx founded?
ArcherDx was founded in 2013.
Where is ArcherDx's headquarters?
ArcherDx's headquarters is located at 2477 55th Street, Boulder.
What is ArcherDx's latest funding round?
ArcherDx's latest funding round is Acquired - II.
How much did ArcherDx raise?
ArcherDx raised a total of $150M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.